CHARACTERIZATION OF THE EXOGENOUS INTERLEUKIN-2 REQUIREMENTS FOR THE GENERATION OF ENHANCED ANTITUMOR CYTOTOXICITY BY THYMOCYTES FROM LOW-DOSE MELPHALAN-TREATED MOPC-315 TUMOR BEARERS

被引:3
作者
RUBIN, M
MOKYR, MB
机构
[1] Department of Microbiology and Immunology, University of Illinois at Chicago, Chicago, 60680, Illinois
关键词
LOW-DOSE CHEMOTHERAPY; THYMIC IMMUNE REACTIVITY; ANTITUMOR CYTOTOXICITY; PROLIFERATION; IL-2;
D O I
10.1007/BF01789129
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have shown previously that thymocytes from MOPC-315-tumor-bearing mice treated with low-dose melphalan (L-phenylalanine mustard) (L-PAM TuB mice) are superior to thymocytes from untreated MOPC-315-tumor-bearing mice or thymocytes from untreated normal mice or normal mice treated with low-dose melphalan in their ability to generate an antitumor cytotoxic response following 5-day in vitro stimulation with MOPC-315 tumor cells in the presence of a low concentration of recombinant interleukin-2 (rIL-2) [Mokyr MB, Bartik MM, Ahn M-C (1989) Cancer Res 49; 8701. Here we characterize the rIL-2 requirements for the generation of enhanced antitumor cytotoxicity by L-PAM TuB thymocytes relative to normal thymocytes upon in vitro stimulation with MOPC-315 tumor cells. Specifically, we show that delaying the addition of a low concentration of rIL-2 to 5-day in vitro stimulation cultures of thymocytes resulted in a progressive decline in the generation of antitumor cytotoxicity by both normal and L-PAM TuB thymocytes. However, even when rIL-2 was added on day 2 after culture initiation, thymocytes from L-PAM TuB mice generated a more potent antitumor cytotoxicity than did thymocytes from normal mice. In addition, when rIL-2 was added at the time of culture initiation, replacement of the conditioned medium with fresh medium lacking rIL-2 on day 3 of the 5-day in vitro stimulation culture period eliminated the ability of normal thymocytes, and reduced (but did not eliminate) the ability Of L-PAM TuB thymocytes, to generate a significant level of antitumor cytotoxicity. A low concentration of fresh rIL-2 was sufficient to restore completely the generation of antitumor cytotoxicity by normal or L-PAM TuB thymocytes when added to the stimulation cultures immediately after the removal of the rIL-2-containing conditioned medium. The same low concentration of rIL-2 was also sufficient for restoring the generation of antitumor cytotoxicity by cultures Of L-PAM TuB thymocytes, but not normal thymocytes, from which the rIL-2-containing medium was removed 1 day earlier. At the same time, conditioned medium from stimulation cultures Of L-PAM TuB thymocytes was not superior to conditioned medium from stimulation cultures of normal thymocytes in supporting the generation of antitumor cytotoxicity by either normal or L-PAM TuB thymocytes. Thus, the enhanced lytic activity generated by L-PAM TuB thymocytes, relative to normal thymocytes, upon stimulation with MOPC-315 tumor cells and a low concentration of rIL-2, does not appear to be the result of enhanced production of helper-like factors by L-PAM TuB thymocytes.
引用
收藏
页码:37 / 44
页数:8
相关论文
共 23 条
[1]   ENHANCED EXPANSION OF THE THYMIC CD8+ CELL SUBSET AS A POTENTIAL MECHANISM FOR THE GENERATION OF ENHANCED ANTITUMOR CYTOTOXICITY BY THYMOCYTES FROM LOW-DOSE MELPHALAN-TREATED MOPC-315 TUMOR BEARERS [J].
BARTIK, MM ;
BAUMGARTELSCOFIELD, BA ;
MOKYR, MB .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1991, 34 (02) :79-89
[2]   PRESENCE OF AN ENLARGED POOL OF MOPC-315-SPECIFIC CYTOTOXIC LYMPHOCYTE-T PRECURSORS IN THE THYMUSES OF MICE THAT ERADICATED A LARGE MOPC-315 TUMOR AS A CONSEQUENCE OF LOW-DOSE MELPHALAN THERAPY [J].
BARTIK, MM ;
AHN, MC ;
BAUMGARTEL, BA ;
HENDRICKS, RL ;
MOKYR, MB .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1990, 32 (03) :143-153
[3]  
BENEFRAIM S, 1983, CANCER IMMUNOL IMMUN, V15, P101
[4]  
BERD D, 1986, CANCER RES, V46, P2572
[5]   TREATMENT OF METASTATIC MELANOMA WITH AN AUTOLOGOUS TUMOR-CELL VACCINE - CLINICAL AND IMMUNOLOGICAL RESULTS IN 64 PATIENTS [J].
BERD, D ;
MAGUIRE, HC ;
MCCUE, P ;
MASTRANGELO, MJ .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (11) :1858-1867
[6]   TUMORICIDAL AND IMMUNOMODULATORY ACTIVITIES OF DRUGS AND IMPLICATIONS FOR THERAPY OF MICE BEARING A LATE STAGE MOPC-315-PLASMACYTOMA [J].
BERKO, R ;
SEISSMAN, K ;
COLVIN, M ;
BOCIAN, RC ;
BENEFRAIM, S ;
DRAY, S .
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1988, 10 (07) :825-834
[7]  
HENGST JCD, 1980, CANCER RES, V40, P2135
[8]  
HENGST JCD, 1981, CANCER RES, V41, P2163
[9]   CYCLOPHOSPHAMIDE AND ABROGATION OF TUMOR-INDUCED SUPPRESSOR T-CELL ACTIVITY [J].
HOOVER, SK ;
BARRETT, SK ;
TURK, TMT ;
LEE, TC ;
BEAR, HD .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1990, 31 (02) :121-127
[10]  
KONARD MW, 1990, CANCER RES, V50, P2009